Inside Sionna’s Bid To Normalize CFTR Function

About this episode

Two leaders from Sionna Therapeutics discuss their journey in advancing therapies for cystic fibrosis.

Send us Fan Mail Two leaders from Sionna Therapeutics walk through a 15‑year journey from Genzyme science to a public company advancing NBD1‑targeted therapies in cystic fibrosis. We examine why most patients still fall short of normal CFTR, how a predictive assay de‑risks choices, and what it takes to finance, hire, and execute with patients as the North Star. Visit: sionnatx.com Visit Labtolives.com Do you want to try the quiz from this episode? Find the link on our LinkedIn profile: h...

People in this episode

Host: Ivanna Rosendal

Guest: two leaders from Sionna Therapeutics

Topics covered

• cystic fibrosis
• therapies
• healthcare
• biotechnology
• patient care

Keywords

• cystic fibrosis
• CFTR function
• NBD1-targeted therapies
• predictive assay
• patient care

Mentioned in this episode

Organizations: Sionna Therapeutics, Genzyme, sionnatx.com, Labtolives.com

More episodes of Lab to Lives

• What If The Real Blocker Is Coordination Not Data w/ Anastasia Christianson · June 10, 2026 · 52 min
• Electrifying the Factory: Agentic AI For Faster Clinical Trials with Pamela Tenaerts · May 13, 2026 · 49 min
• Why Big Pharma Feels Like A Financial Institution & Don't Pee on Medical Gloves with Anish Shindore · April 15, 2026 · 1h 9m
• How Biotech Ideas Become Real Patient Impact w/ new co-hosts Alex and Dimitri · March 30, 2026 · 49 min
• Dear Pharma, Your Patient Isn’t A KPI with Mark Duman · March 3, 2026 · 25 min
• Audit Trails, RBQM, And Agentic AI Explained · February 11, 2026 · 39 min